<DOC>
	<DOCNO>NCT02109575</DOCNO>
	<brief_summary>The primary goal Multicenter Study develop evaluate method measure donor-specific cell free DNA blood sample transplant recipient marker rejection . Blood sample obtain periodically heart transplant recipient assess cell free DNA relative clinical data order determine whether change level cell free DNA indicate rejection . This research study propose test blood sample obtain heart transplant recipient . The research seek establish whether blood test show patient begin already reject transplant heart . BACKGROUND Identifying transplant patient begin already reject heart necessary , appropriate treatment start halt rejection . Heart catheterization biopsy usual method use assess whether patient may reject heart . There also number method transplant physician use look sign rejection include blood test , echocardiogram , obtain pressure reading heart catheterization , micro-array test blood obtain biopsy . These technology limit ability consistently accurately identify presence rejection . The usual method check rejection involve obtain sample heart tissue ( heart biopsy ) ; biopsy accomplish heart catheterization invasive procedure risk associate disturb heart puncture heart cause heart rate change damage tissue heart . Overtime , repeat invasive procedure diminish ease procedure vein become scarred difficult access . For reason , researcher believe would good blood test give information possibility rejection may necessary many heart biopsy . Also , blood test may able provide information heart rejection currently available .</brief_summary>
	<brief_title>Quantitative Detection Circulating Donor-Specific DNA Organ Transplant Recipients ( DTRT-Multi-Center Study )</brief_title>
	<detailed_description>Early detection rejection major focus organ transplant care . The use aggressive immunosuppressive therapy show alter prognosis heart transplant patient acute rejection1 . There many modality utilized routine surveillance heart transplant patient , limitation . Screening transthoracic echocardiography focus index systolic diastolic dysfunction , along regional wall abnormality , show poor sensitivity effectively discriminate patient without rejection . Newer echocardiographic parameter include myocardial performance diastolic velocity index may better mean detect subtle change cardiac function set heart transplant , tool helpful insult cause rejection already occur . Hemodynamic change measure heart catheterization also evaluate mean detect rejection . Rosenthal et al find although statistically significant difference patient high low grade rejection score , heart catheterization permit effective discrimination patient moderate severe rejection . Heart biomarkers , include c-reactive protein , brain natriuretic peptide , troponin , study non-invasive measure determine heart dysfunction rejection . These surrogate weakly associate different rejection grade biopsy poor predictive capacity biopsy-detected rejection3 . Recently , microarray technology use screen gene express heart allograft rejection use peripheral leukocyte blood sample obtain time endomyocardial biopsy . This technique show high negative predictive value diagnosis acute cellular rejection unable detect low grade rejection4 . Overall , technology limit ability consistently accurately predict presence rejection low positive predictive value compare biopsy . The current gold standard detection rejection use endomyocardial biopsy . Attaining sample invasive long term repeat central venous access difficult . Risk endomyocardial biopsy include perforation lead cardiac tamponade , arrhythmias include atrial fibrillation , pneumothorax , hemothorax , valvular regurgitation secondary rupture chordae damage valve leaflet . There variability pathological interpretation histologic grade , especially high grades rejection due difficulty interpretation nodular infiltrates . The 2005 revise ISHLT grade system simplify grade system cellular rejection include assessment antibody mediate rejection . This may improve utility endomyocardial biopsy , much controversy still exist method grade rejection clinical implication . Thus , development noninvasive , relatively inexpensive method accurately predict presence rejection critical .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Any patient `` list '' undergo past undergone heart transplantation . Any patient currently list undergo heart transplantation previously receive heart transplant ; Any patient anticipate available followup least 1 year ; Any patient unable unwilling provide document informed consent self legally authorize representative .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Rejection</keyword>
	<keyword>Cardiac Biomarkers</keyword>
	<keyword>Cardiac Catheterization</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Cell-Free DNA</keyword>
	<keyword>Congenital Heart Defect</keyword>
	<keyword>Congenital Heart Disease</keyword>
	<keyword>Coronary Angiogram</keyword>
	<keyword>Donor Specific DNA</keyword>
	<keyword>Donor Specific Cell-Free DNA</keyword>
	<keyword>Endomyocardial Biopsy</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Transplant Failure</keyword>
	<keyword>Heart Transplant</keyword>
	<keyword>Heart Transplant Rejection</keyword>
</DOC>